Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma

Journal of Gastroenterology

Volumn 49, Issue 12, 2014, Pages 1578-1587

  Arizumi, Tadaaki ^a   Ueshima, Kazuomi ^a   Takeda, Haruhiko ^b   Osaki, Yukio ^b   Takita, Masahiro ^a   Inoue, Tatsuo ^a   Kitai, Satoshi ^a   Yada, Norihisa ^a   Hagiwara, Satoru ^a   Minami, Yasunori ^a   Sakurai, Toshiharu ^a   Nishida, Naoshi ^a   Kudo, Masatoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Hypervascular lesion; Liver cirrhosis; Response evaluation criteria in cancer of the liver; Response evaluation criteria in solid tumors; Tumor viability

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRITERION VARIABLE; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MODIFIED RESPONSE EVALUATION CRITERION IN SOLID TUMORS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTION; RESPONSE EVALUATION CRITERION IN CANCER OD THE LIVER; RESPONSE EVALUATION CRITERION IN SOLID TUMORS 1.1; SURVIVAL RATE; SURVIVAL TIME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; KAPLAN MEIER METHOD; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84916244854     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0936-0     Document Type: Article

References (15)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
2. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
3. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology. 2011;81:24–9.
4. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both RAF and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–40.
5. Rini BI. Sorafenib. Expert Opin Pharmacother. 2006;7:453–61.
6. Wu H, Huang C, Chang D. Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol. 2008;4:37–45.
7. Kano MR, Komuta Y, Iwata C, et al. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci. 2009;100:173–80.
8. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009;100:1–8.
9. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–27.
10. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
12. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
13. The Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer. 5th ed. Tokyo: Kanehara; 2009 (revised version).
14. Miller AB, Hogestraeten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–14.
15. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042–50.